XSHG
600062
Market cap2.74bUSD
Dec 05, Last price
18.79CNY
1D
-0.42%
1Q
-3.04%
Jan 2017
21.70%
Name
China Resources Dubl-Crne Phrmctl Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||